Clientfirst Wealth Management LLC Makes New $228,000 Investment in ARK Genomic Revolution ETF (BATS:ARKG)

Clientfirst Wealth Management LLC acquired a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 9,670 shares of the company’s stock, valued at approximately $228,000.

A number of other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in ARK Genomic Revolution ETF by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock valued at $75,655,000 after acquiring an additional 698,701 shares during the last quarter. Atom Investors LP boosted its stake in shares of ARK Genomic Revolution ETF by 15.2% in the 3rd quarter. Atom Investors LP now owns 49,131 shares of the company’s stock valued at $1,258,000 after purchasing an additional 6,496 shares in the last quarter. Barclays PLC grew its holdings in shares of ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after purchasing an additional 204,283 shares during the last quarter. Elmwood Wealth Management Inc. grew its holdings in shares of ARK Genomic Revolution ETF by 39.7% during the 3rd quarter. Elmwood Wealth Management Inc. now owns 57,766 shares of the company’s stock valued at $1,479,000 after purchasing an additional 16,412 shares during the last quarter. Finally, National Bank of Canada FI raised its position in ARK Genomic Revolution ETF by 28.4% in the 3rd quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock worth $106,000 after purchasing an additional 920 shares during the period.

ARK Genomic Revolution ETF Stock Up 14.1 %

BATS ARKG opened at $26.94 on Friday. The company’s 50-day simple moving average is $25.42 and its 200-day simple moving average is $25.24.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.